Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. Co. has developed a resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL™, has various potential indications of use for diseases, which of Co. is primarily targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes syndrome and with Amyotrophic Lateral Sclerosis in an early development stage. In the larger disease areas, Co. is primarily targeting Mild Cognitive Impairment/early Alzheimer's disease with Traumatic Brain Injury /concussions and Covid-19 in early development stages. We show 4 historical shares outstanding datapoints in our coverage of JUNS's shares outstanding history.
Understanding the changing numbers of JUNS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like JUNS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching JUNS by allowing them to research JUNS shares outstanding history
as well as any other stock in our coverage universe. |
Free JUNS Email Alerts:
Video: Shares Outstanding Importance
